Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells
Open Access
- 6 November 2009
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 59 (4) , 609-618
- https://doi.org/10.1007/s00262-009-0788-2
Abstract
The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause for variability and suboptimal performance in large international Elispot proficiency panels. Therefore, a serum task force was initiated to compare the performance of commercially available serum-free media to laboratories’ own medium/serum combinations. The objective of this project was to investigate whether a serum-free medium exists that performs as well as lab-own serum/media combinations with regard to antigen-specific responses and background reactivity in Elispot. In this way, a straightforward solution could be provided to address the serum challenge. Eleven laboratories tested peripheral blood mononuclear cells (PBMC) from four donors for their reactivity against two peptide pools, following their own Standard Operating Procedure (SOP). Each laboratory performed five simultaneous experiments with the same SOP, the only difference between the experiments was the medium used. The five media were lab-own serum-supplemented medium, AIM-V, CTL, Optmizer, and X-Vivo. The serum task force results demonstrate compellingly that serum-free media perform as well as qualified medium/serum combinations, independent of the applied SOP. Recovery and viability of cells are largely unaffected by serum-free conditions even after overnight resting. Furthermore, one serum-free medium was identified that appears to enhance antigen-specific IFNγ-secretion.Keywords
This publication has 21 references indexed in Scilit:
- Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCancer Immunology, Immunotherapy, 2009
- Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccinesCancer Immunology, Immunotherapy, 2008
- A chromatic explosion: the development and future of multiparameter flow cytometryImmunology, 2008
- Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detectionJournal of Immunological Methods, 2008
- Toward the harmonization of immune monitoring in clinical trials: Quo vadis?Cancer Immunology, Immunotherapy, 2007
- The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assaysCancer Immunology, Immunotherapy, 2007
- A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCsJournal of Immunotherapy, 2007
- Evaluation of Elispot assays: influence of method and operator on variability of resultsJournal of Immunological Methods, 2004
- A modified human ELISPOT assay to detect specific responses to primary tumor cell targetsJournal of Translational Medicine, 2004
- Direct Visualization of Cytokine-Producing Recall Antigen-Specific CD4 Memory T Cells in Healthy Individuals and HIV PatientsThe Journal of Immunology, 2000